2024
Living on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff
Udelsman B, Bedrosian C, Kawaguchi E, Ding L, Wallace W, Rosenberg G, Harano T, Wightman S, Atay S, Kim A, Woodard G. Living on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 39521371, DOI: 10.1016/j.jtcvs.2024.10.053.Peer-Reviewed Original ResearchNon-small cell lung cancerSystemic therapyOverall survivalT stageTumor sizeResected non-small cell lung cancerLung cancerNational Cancer Database of patientsResection of primary lung cancerOutcomes of systemic therapyPathologic tumor sizeNational Cancer DatabaseAdjuvant therapy useUse of systemic therapyPrimary lung cancerResection of tumorsCell lung cancerAssociated with decreased ratesDatabase of patientsRetrospective cohort studyTumor size distributionDownstaged patientsNodal involvementUnder-stagingAdjuvant therapy
2016
Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity
Woodard GA, Crockard JC, Clary‐Macy C, Zoon‐Besselink C, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity. Journal Of Surgical Oncology 2016, 114: 838-847. PMID: 27569043, DOI: 10.1002/jso.24409.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinomaChemoradiotherapy, AdjuvantEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansLaparoscopyMaleMiddle AgedMinimally Invasive Surgical ProceduresNeoadjuvant TherapyNeoplasm Recurrence, LocalNeuroendocrine TumorsPostoperative ComplicationsProspective StudiesSurvival AnalysisThoracotomyTreatment OutcomeConceptsNeoadjuvant chemoradiationEsophagectomy approachesLong-term overall survival rateInvasive Ivor Lewis esophagectomyLow perioperative morbidityPostoperative complication rateClear survival benefitFive-year survivalIvor Lewis esophagectomyMajority of patientsOverall survival rateEsophageal cancer patientsInvasive esophagectomy (MIE) approachPatients 58Hospital stayNeoadjuvant treatmentPerioperative complicationsPerioperative morbidityPostoperative complicationsProspective databaseClinical characteristicsOverall survivalSurvival benefitComplication rateMajor complicationsLung Cancer Staging and Prognosis
Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treatment And Research 2016, 170: 47-75. PMID: 27535389, DOI: 10.1007/978-3-319-40389-2_3.Peer-Reviewed Original ResearchConceptsTNM stageLung Cancer Lung Cancer Staging ProjectCancer TNM staging systemLung Cancer Staging ProjectSurvival estimatesIndividualized survival estimatesNew immunotherapy drugsStage IA diseaseStage IV diseaseImportant prognostic factorTNM staging systemPoor prognostic indicatorMolecular prognostic markersSignificant survival differenceTumor histologic gradeLung cancer stagingMolecular tumor profilingGenetic tumor analysisIA diseaseTNM groupingsOverall survivalPerformance statusMolecular prognosticationPD-L1Prognostic factorsConsensus Report of the 2015 Weinman International Conference on Mesothelioma
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal Of Thoracic Oncology 2016, 11: 1246-1262. PMID: 27453164, PMCID: PMC5551435, DOI: 10.1016/j.jtho.2016.04.028.Peer-Reviewed Original ResearchConceptsMalignant mesotheliomaOverall survivalHigh mobility group box 1Mobility group box 1Development of MMIncidence of MMGroup box 1Novel therapeutic approachesNational Cancer InstitutePublic health authoritiesU.S. National Cancer InstitutePreventable malignancyStandard chemotherapyCancer CenterBlood biomarkersLung cancerMineral fibersClinical trialsCurrent treatmentOccupational exposureProtein 1 mutationConsensus reportTherapeutic approachesGermline BRCA1Clinical Oncology
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic marker